MedTrace Logo

A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole

NCT03980756 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2021-01-13

No results posted yet for this study

Summary

A study to compare safety, pharmacokinetics and pharmacodynamics of AD-206 to Esomeprazole in healthy male volunteers.

Conditions

  • Gastritis

Interventions

DRUG

AD-206 20mg

1 tablet administered before the breakfast during 7 days

DRUG

Esomeprazole 20mg

1 tablet administered before the breakfast during 7 days

DRUG

AD-206 40mg

1 tablet administered before the breakfast during 7 days

DRUG

Esomeprazole 40mg

1 tablet administered before the breakfast during 7 days

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • In-Jin Jang, M.D.,Ph.D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-05
Primary Completion
2020-04-27
Completion
2020-06-18

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03980756 on ClinicalTrials.gov